Blueprint Medicines Cash Flow Statement

Financials in millions INR. Fiscal year is April - March.

Millions INR. Fiscal year is Apr - Mar.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2016 - 2020
Period Ending	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021	2016 - 2020
Net Income	12.17	122.91	6	61.76	95.42	Upgrade
Depreciation & Amortization	0.96	0.05	0.1	0.26	0.26	Upgrade
Other Amortization	-	0.04	0.03	0.02	0.03	Upgrade
Asset Writedown & Restructuring Costs	-7.71	-76.58	24.62	-48.09	-67.95	Upgrade
Other Operating Activities	-38.16	-14.88	-2.15	4.49	-2.47	Upgrade
Change in Accounts Receivable	0.89	132.88	-134.12	-0.28	-	Upgrade
Change in Other Net Operating Assets	41.11	-84.68	-101.94	10.98	41.99	Upgrade
Operating Cash Flow	1.08	-22.82	-1.03	3.84	-11.39	Upgrade
Capital Expenditures	-9.91	-0.05	-	-	-0.15	Upgrade
Sale of Property, Plant & Equipment	0	-	-	-	-	Upgrade
Sale (Purchase) of Intangibles	-	-0.05	-0.11	-	-	Upgrade
Other Investing Activities	26.49	24.33	13.03	11.53	11.81	Upgrade
Investing Cash Flow	16.59	24.24	12.93	11.53	11.66	Upgrade
Common Dividends Paid	-18.87	-	-12.58	-15.72	-	Upgrade
Financing Cash Flow	-18.87	-	-12.58	-15.72	-	Upgrade
Miscellaneous Cash Flow Adjustments	-	-	-	-	0	Upgrade
Net Cash Flow	-1.2	1.42	-0.68	-0.35	0.28	Upgrade
Free Cash Flow	-8.82	-22.87	-1.03	3.84	-11.53	Upgrade
Free Cash Flow Margin	-31.11%	-13.14%	-5.45%	5.25%	-9.90%	Upgrade
Free Cash Flow Per Share	-0.84	-2.18	-0.10	0.37	-1.10	Upgrade
Cash Income Tax Paid	13.4	28.78	-7.49	0.98	5.66	Upgrade
Levered Free Cash Flow	-891.32	243.03	-117.44	64.31	79.54	Upgrade
Unlevered Free Cash Flow	-891.32	243.03	-117.44	64.31	79.54	Upgrade
Change in Net Working Capital	891.06	-142.31	123.33	-14.8	-10.39	Upgrade

Updated Feb 5, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.